Divi's Labs Shares Surge Over 3% After Q1FY27 Earnings Results: Net Profit Jumps 65.5% YoY to ₹902 Crore

Divi's Laboratories reported a consolidated net profit of ₹902 crore for the quarter ended June 30, 2026, up 65.5% from ₹545 crore in the corresponding quarter last year, as per the exchange filings.  

Revenue from operations increased 28% year-on-year to ₹3,080 crore, compared with ₹2,410 crore a year ago. Total income for the quarter stood at ₹3,144 crore, marking a rise of over 24% year-on-year. Meanwhile, total expenses increased by more than 9% to ₹1,964 crore. 

Profit Before Tax Improves Despite Forex Loss 

Profit Before Tax (PBT) rose to ₹1,180 crore, compared with ₹733 crore in the same quarter of the previous financial year. The company, however, reported a foreign exchange loss of ₹7 crore, against a forex gain of ₹39 crore recorded in the year-ago period. 

Separately, the board approved the appointment of B Vara Prasad and J Srinivasa Rao as senior management personnel with effect from August 1, 2026. 

Market Capitalisation Moves Higher 

Following the earnings announcement, Divi's Laboratories moved ahead of Eicher Motors and Hindalco Industries in terms of market capitalisation.  

On August 3, 2026, at around 11:35 am, the company's market value stood at approximately ₹2.25 trillion, compared with ₹2.22 trillion for Hindalco and ₹2.21 trillion for Eicher Motors. 

Among listed pharmaceutical companies, Divi's Laboratories is now the second-largest by market capitalisation after Sun Pharmaceutical Industries. It ranks ahead of Torrent Pharmaceuticals, Cipla, Zydus Lifesciences, Lupin and Mankind Pharma. 

Read More: Aether Industries and Dow India Launch Research Programme to Develop Silicone Manufacturing Technology! 

Divi's Laboratories Share Price Performance  

As of August 3, 2026, 2:17 pm, Divi's Laboratories share price was trading at ₹8,357.00, up 3.74% from the previous closing price. 

Conclusion 

Divi's Laboratories reported higher revenue and profit for the June quarter, while the post-results rally lifted its market capitalisation above Hindalco Industries and Eicher Motors. The company is now the second-largest listed pharmaceutical firm in India by market value. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.   
 
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.